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cation prescriptions; reliance on pharmacotherapy in obesity treatment; the odds 
of a specific patient’s being prescribed antiobesity medication; and consistency of 
prescribing with the 1998 obesity guidelines. METHODS: Data for adult patients 
were obtained from the National Ambulatory Medical Care Survey and the National 
Hospital Ambulatory Medical Care Survey, and were appropriately weighted to pro-
duce national estimates of prescribing patterns. Obesity was identified using ICD-9 
codes, BMI values, and a chronic-obesity-condition variable. For obese patients, a 
logistic regression model was estimated to determine the odds of receiving phar-
macotherapy. RESULTS: The number of outpatient visits with any mention of an 
antiobesity medication increased from 6.5 million from 1999-2001 to 13.0 million 
from 2008-2010. Only 2.0% of the 987 million obese-patient visits from 2005-2010 
mentioned an antiobesity drug. Additionally, there were 6.5 million visits by nonobese 
patients with an antiobesity drug mention. Visits made by females (OR = 2.89; 95% 
CI: 2.08–4.03), by white patients (OR = 1.55; 95% CI: 1.08–2.24), by younger adults (OR 
= 1.71; 95% CI: 1.34–2.20), and in the South (OR = 3.39; 95% CI: 1.49–7.72) were more 
likely to involve an antiobesity drug prescription. CONCLUSIONS: Pharmacotherapy 
has been underutilized as a treatment option for obese patients. Only 1 in 50 patients 
is receiving a prescription for an antiobesity medication. Prescribing regulations and 
drug safety concerns have clearly discouraged the use of pharmacotherapy. Moreover, 
in contrast to what the 1998 guidelines suggested, physicians have tended to prescribe 
antiobesity medications to self-paying young, white, females, many of whom lived in 
the South, and not all of whom were obese; they have tended not to prescribe them 
to patients with comorbidities like hypertension.
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ImPlementatIon of a StatewIde oPIate PreScrIbIng PolIcY IS not 
aSSocIated wIth a SIgnIfIcant decreaSe In oPIate PreScrIPtIonS from 
the emergencY dePartment
McGhee J.D., Bounds R.B., Papas M.A., Coletti C.
Christiana Care Health System, Newark, DE, USA
OBJECTIVES: Determine whether the implementation of a statewide opiate prescrib-
ing policy is associated with a decrease in the number of prescriptions for opiates 
for discharged emergency department patients. METHODS: Retrospective review of 
opiate prescriptions written by medical professionals comparing a 4 month period 
before and after the implementation of an opiate prescribing policy. RESULTS: An 
independent samples t-test was conducted to examine the differences in the mean 
number of total prescriptions per patient per day, opiate prescriptions per patient 
per day, total number of visits per day, and total number of opiate prescriptions per 
day. In the four-month period prior to implementation of the policy, there was an 
average of 0.196 (SD= 0.005) opiate prescriptions per patient per day. This decreased 
to 0.188 (SD= 0.015) opiate prescriptions per patient per day in the four-month period 
after the policy. The difference was not statistically significant (mean difference 
= 0.009; 95% CI: -0.014, 0.03; p = 0.35). Before the policy, there was also an average 
of 0.84 (SD= 0.015) prescriptions/day and, after the policy, this decreased to 0.79 
(SD= 0.04) prescriptions/day (mean difference = 0.046; 95% CI:-0.018, 0.11; p = 0.10). 
The average number of total visits per day decreased over this time period (483 
(SD= 4.1) vs, 463 (SD= 11.2); mean difference= 20.2; 95% CI: 3.2, 36.8; p = 0.03) as did the 
total number of opiate prescriptions per day (405 (SD= 4.5) vs 367 (SD= 27.9); mean 
difference= 37.7; 95%CI: -4.9, 82.7; p = 0.07). CONCLUSIONS: Controlling for daily 
emergency department volume and total prescriptions, the proportion of prescrip-
tions written for opiates remained relatively unchanged with the implementation 
of a statewide opiate prescribing policy. This may indicate that the effect of prescrib-
ing policies cannot be accurately measured using number of prescriptions written. 
Alternatively, quantity of pills per prescription may be a more appropriate measure 
of such a policy’s success.
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OBJECTIVES: The CMS Medicare Part D Overutilization Monitoring System and 
Pharmacy Quality Alliance (PQA) draft overutilization measures include members 
receiving opioid prescriptions from ≥ 4 prescribers and ≥ 4 pharmacies (“shoppers”). 
This study examines the impact of varying prescriber and pharmacy definitional 
thresholds on the prevalence of overutilization and the likelihood of drug abuse 
indicators in shoppers and non-shoppers. METHODS: Medical and pharmacy claims 
for 2013 from adult, non-cancer, commercial and Medicare members in the Humana 
Research Database (Humana, Louisville, KY) receiving ≥ 2 prescriptions for an opioid 
were analyzed. Overutilization prevalence was examined for thresholds of ≥ 3 to ≥ 6 
prescribers and for ≥ 3 to ≥ 6 pharmacies. For each combination, the odds ratios of 
shoppers to non-shoppers for presence of an opioid abuse diagnosis, non-opioid 
drug abuse diagnosis, and prescription for other commonly abused medications 
(e.g., stimulants, benzodiazepines) were calculated. RESULTS: In the final study 
cohort (n= 359,656), prevalence of overutilization ranged from 5.48% at the ≥ 3 pre-
scriber and ≥ 3 pharmacy definition to 0.17% at ≥ 6 prescribers and ≥ 6 pharmacies. 
The percentage of shoppers with an opioid abuse diagnosis was 12.26% and 28.11%, 
respectively, for those two definitions. For the ≥ 4 prescriber and ≥ 4 pharmacy case, 
shoppers (1.48% prevalence) were 4.43 times more likely than non-shoppers to have 
a diagnosis of opioid abuse (95%CI 4.13-4.75; p< 0.001), 2.52 times more likely to have 
a diagnosis for other drug abuse (95%CI 2.40-2.65; p< 0.001), and 1.65 times more 
likely to have pharmacy claims for other commonly abused medications (95%CI 
1.58-1.73; p< 0.001). Poster will include results for shoppers and non-shoppers 
across all threshold combinations studied. CONCLUSIONS: These results can aid 
the development and interpretation of opioid overutilization quality measures and 
support better informed intervention strategies to address the public health crisis 
of prescription drug abuse.
(< 1/100,000) were given no points; conditions with incidence > 1/5000 were given 
100 points. Intermediate incidence data received intermediate points (25/50/75). 
Alongside these scores was an assessment by ACMG of the incidence. We rescored 
the question using the ACMG’s facts on incidence for each condition to see how 
this would affect total scores and recommendations. RESULTS: After eliminating 
conditions with missing data, 78 remained. All had score changes. We (arbitrarily) 
defined a positive score change as one where the fact-based score was less than 
the opinion-based score (OBS – FBS > 0). Most of the changes were positive (74%). 
The range was from -37 to +68. The overall mean change was +4 (for positive and 
negative changes, +12.7 and –20.4). There were two EPA changes, but only one 
had potential to lead to a change in final recommendation. Thirteen (17%) of the 
others moved to within 50 points of an EPA change. CONCLUSIONS: Rescoring 
this one question had minimal effect on the EPA and therefore on the final ACMG 
recommendations, however, we only explored one question of the 19. Similar 
adjustments to other survey responses could reinforce trends seen here and result 
in more reclassifications.
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how much IS nIce reallY PrePared to PaY for orPhan and end-of-lIfe 
drugS?
Griffiths E.A., Martin R.L.
HERON Commercialization, London, UK
OBJECTIVES: New health technologies are required to demonstrate clinical and cost-
effectiveness before recommendation by the National Institute for Health and Care 
Excellence (NICE) for reimbursement in England; however, higher cost-effectiveness 
thresholds may be considered for orphan and end-of-life (EOL) therapies. To help 
inform future submissions, the incremental cost-effectiveness ratios (ICERs) of – 
and rationale behind – accepted NICE submissions for orphan and EOL therapies 
were assessed. METHODS: All NICE single technology appraisals from January 
2009 to December 2014 were included in the analysis. The decision, rationale, and 
manufacturer’s ICER (including patient access scheme where applicable) for each 
submission were extracted. Appraisals were then assessed for meeting NICE EOL 
or European orphan drug criteria. Multiple technology appraisals, resubmissions, 
vaccination programmes, requests for advice, and submissions where an ICER could 
not be determined were excluded. RESULTS: Of 111 relevant NICE submissions, 12 
met orphan drug criteria, 16 met EOL criteria and 4 met both. For orphan drugs, 8/12 
(67%) were accepted, with a mean ICER of £33,725 for accepted submissions (range: 
£24,544 - 56,693). For EOL drugs, 12/16 (75%) were accepted, with a mean ICER of 
£40,906 for accepted submissions (range: £14,795-£62,829). This compared with an 
overall acceptance rate for non-orphan/EOL NICE submissions of 71/87 (82%), with 
a mean ICER of £15,303 for accepted submissions (range: £1,537-£35,208). Rationale 
for acceptance of orphan and EOL drug submissions included unmet therapeutic 
need, lack of alternative treatment options, and innovation. CONCLUSIONS: Based 
on the evidence, NICE’s decision threshold was significantly higher for orphan/EOL 
drugs than for others (p< 0.001). However, the overall acceptance rate was lower, 
and restrictions to patient sub-populations as well as patient access schemes were 
often applied. Nevertheless, the incorporation of elements such as unmet need into 
the decision-making process makes high ICERs appropriate where there is strong 
evidence of demonstrable clinical benefit.
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how InfluentIal are PatIent and ProfeSSIonal grouP SubmISSIonS 
on reImburSement decISIonS for euroPean medIcIneS agencY orPhan 
drugS?
Chang R., Versoza L., Jaksa A., Ho Y.
Context Matters, New York, NY, USA
OBJECTIVES: Uncertainty often surrounds orphan-drug reimbursement, given the 
small sample sizes and limited availability of clinical trials. Consequently, manufac-
turers and Health Technology Assessment (HTA) agencies are turning to real-world 
evidence to understand the patient experience. Both SMC and NICE encourage 
patient/professional group involvement in the HTA reimbursement process, but 
do these submissions influence reimbursement decisions? METHODS: Using the 
Context Matters’ proprietary database, the analysis was restricted to full HTA submis-
sions from NICE and SMC for European Medicines Agency (EMA) orphan drugs. The 
reimbursement decision, the presence of a patient/professional group submission, 
and any agency comments on the submissions were extracted from each assessment. 
Reimbursement decisions were categorized as either positive or negative. RESULTS: 
Fifty assessments across 13 disease conditions were analyzed. There was no associa-
tion between patient/professional group submissions and positive reimbursement 
decisions (p= 0.70); 48% (20) of assessments with a patient/professional group submis-
sion resulted in a positive decision while 52% (22) of assessments with a patient/pro-
fessional group submission resulted in a negative decision. When stratified by agency 
or disease condition, there was still no relationship between decision and patient/pro-
fessional group submission. Individual assessments were examined to determine how 
SMC and NICE use patient/professional group submissions. CONCLUSIONS: Results 
indicate that patient/professional group submissions are not directly associated with 
positive reimbursement decisions; this presentation will detail how SMC and NICE use 
these submissions in their decision-making. Due to the increasing rate of develop-
ment in the orphan-drug space and the importance of incorporating the patient voice, 
manufacturers need to understand how these submissions influence HTA agencies.
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treatment of obeSItY: PharmacotheraPY trendS In the unIted 
StateS from 1999 to 2010
Xia Y., Kelton C.M., Heaton P.C., Guo J.J.
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: To determine the antiobesity-drug prescribing patterns of U.S. physi-
cians over the last decade (1999-2010) by quantifying trends in antiobesity medi-
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medical costs (2014 purchases and price tabulators) where retrieved to adopt the 
national health system perspective. Information gaps related to the use and fre-
quency of medical resources where fulfilled with the results of a Delphi panel (10 
oncologists of all major public institutions). The model was populated with the 
results of a Network Meta-Analysis. Both probabilistic and deterministic sensitiv-
ity analysis were performed to back up the results. RESULTS: Life years in PFS and 
OS gave an advantage to afatinib with 1.17 and 2.21 years respectively, followed by 
erlotinib with 1.11 and 2.07, gefitnib with 1.02 and 2.12 and pemetrexed/cisplatin 
with 0.63 and 2.07. Least costly therapy was afatinib with total treatment costs 
until death of US$100,152, followed by erlotinib, gefitinib and pemetrexed/cisplatin 
with 141,040 USD, 141,176 USD and 175,889 USD respectively. Afatinib, erlotinib 
and gefitinib resulted dominant therapies against pemetrexed/cisplatin. A further 
analysis showed a dominance of afatinib versus the others TKIs. Results were robust 
to changes in the time horizon (1 to 5 years) and prices (±10%). CONCLUSIONS: 
Afatinib resulted to be a cost-saving therapy against all comparators, presenting 
the least costly treatment and the most life years gained in terms of both PFS and 
OS from a Mexican public health perspective.
cancer – cost Studies (contd.)
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eeconomIc evaluatIon of afatInIb aS the fIrSt lIne treatment 
In PatIentS wIth non-Small cell lung cancer (nSclc) locallY 
advanced or metaStatIc In PreSence of ePIdermal growth factor 
recePtor (egfr) mutatIonS In a meXIcan InStItutIonal conteXt
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OBJECTIVES: To establish the incremental cost-effectiveness ratio (ICER) of tyrosine-
kinase inhibitors (TKIs) afatinib, erlotinib and gefitinib versus pemetrexed/cisplatin 
in presence of EGFR mutations from a public Mexican perspective. Main efficacy 
endpoint was progression free survival (PFS) and secondary endpoint overall sur-
vival (OS). METHODS: A discrete event simulation CE model was developed to 
assess PFS, OS and treatment related costs until death in a five year time hori-
zon. Three relevant clinical health outcomes were assessed in one month length 
cycles: Progression free, disease progression and death. Public institutional direct 
